

I'm writing to formally request that Cologuard (CPT 81528) be added an upcoming MCAC meeting to be added to the Nevada Medicaid fee schedule. This test should already be covered for colorectal cancer screening via the Nevada preventative policy, but for some reason has not been added. Below are the states policies and additional information on Cologuard. More information can be available including budget impact modeling should the need arise. We have the support of many Nevada groups and are working closely with the Nevada Cancer Coalition. Thank you in advance for your consideration.

Cologuard is considered a **COVERED** service per Nevada Preventative Services Policy as it is a USPSTF GRADE A recommended test.

- <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening>
- Covered Services Nevada Medicaid reimburses for preventive health services for men, women and children as recommended by the USPSTF A & B recommendations. The description of the recommendation is the criteria that must be followed for the service to be covered. For the most current list of reimbursable preventive services, please see USPSTF A and B Recommendations as it is subject to change; recommendations are evidence-based and research is conducted for new recommendations regularly. Family planning-related preventive health services as recommended by the USPSTF are a covered benefit.

### USPSTF 2021 Final Recommendation Statement

Recommended Screening Test(s)*	Screening Age	Recommended Screening Intervals	Addressing Disparities
<p><b>Stool-based tests</b></p> <p>sDNA-FIT (Cologuard®)</p> <p>HSgFOBT, FIT</p> <p>Positive results on stool-based screening tests require follow-up colonoscopy for the screening benefits to be achieved</p> <p><b>Direct visualization</b></p> <p>Colonoscopy, CT Colonography, Flexible Sigmoidoscopy +/- FIT</p>	<p><b>Screen adults 50 to 75 years</b></p> <p>Grade A: High certainty that net benefit is substantial</p> <p><b>Screen adults 45 to 49 years</b></p> <p>Grade B: Moderate certainty that net benefit is moderate</p> <p><b>Screen adults 76 to 85 years</b></p> <p>Grade C: Moderate certainty that net benefit is small</p>	<p><b>Stool-based tests</b></p> <p>HSgFOBT, FIT: every 1 year</p> <p>sDNA-FIT (Cologuard®): every 1 to 3 years</p> <p><b>Direct visualization</b></p> <p>Colonoscopy: every 10 years</p> <p>CT colonography: every 5 years</p> <p>Flexible sigmoidoscopy: every 5 years (every 10 years + annual FIT)</p>	<p>Strongly encourages clinicians to ensure Black patients receive recommended colorectal cancer screening, follow-up, and treatment due to historically worse CRC health outcomes.</p> <p>Calls for more research on factors contributing to increased CRC incidence and mortality in Black adults.</p>

\*The USPSTF states: Because no direct evidence compares different screening tests, and because local resources or patient factors may influence feasibility of different screening strategies, the USPSTF is unable to determine which tests are unequivocally "better" or "worse."

Cologuard must be **COVERED** per Nevada State Mandate as it is a recommended test per ACS guidelines

- <https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/acs-recommendations.html>
- **NRS 695G.168 Required provision concerning coverage for screening for colorectal cancer.**
  1. A health care plan issued by a managed care organization that provides coverage for the treatment of colorectal cancer must provide coverage for colorectal cancer screening in accordance with:
    - (a) The guidelines concerning colorectal cancer screening which are published by the American Cancer Society; or
    - (b) Other guidelines or reports concerning colorectal cancer screening which are published by nationally recognized professional organizations and which include current or prevailing supporting scientific data.
  2. An evidence of coverage for a health care plan subject to the provisions of this chapter that is delivered, issued for delivery or renewed on or after October 1, 2003, has the legal effect of including the coverage required by this section, and any provision of the evidence of coverage that conflicts with the provisions of this section is void.

(Added to NRS by [2003, 1337](#))

**Broc Finlayson**

**Mobile:** 608.590.5113 | [bfinlayson@exactsciences.com](mailto:bfinlayson@exactsciences.com)

Exact Sciences Corporation | 145 E. Badger Road, Suite 100, Madison, WI 53713